Antidepressant-like profile and MAO-A inhibitory activity of 4-propyl-2H-benzo[h]-chromen-2-one.

Abstract

AIMS:

To evaluate the central nervous pharmacological profile of 4-propyl-2H-benzo[h]-chromen-2-one (FCS-304) in ICR mice and its monoamine oxidase inhibitor activity.

MAIN METHODS:

FCS-304 was evaluated in screening test of central nervous system in ICR mice and against MAO activity.

KEY FINDINGS:

FCS-304 (25-200mg/Kg, p.o.) significantly reduced immobility time during the forced swimming test (FST) and tail suspension test (TST), but did not show effects in the rota-rod tests, maximal electroshock seizures (MES), pentylenetetrazole seizures, light-dark box, barbiturate sleeping time and cold plate tests. Furthermore, FCS-304 inhibited monoamine oxidase A (MAO-A) with IC50: 2.28+/-0.15microM, but not MAO-B.

SIGNIFICANCE:

These results suggest that FCS-304 could elicit antidepressant effects related to MAO-A inhibitory activity.

• Authors: Nadezdha E Vergel, José L López, Francisco Orallo, Dolores Viña, Diana M Buitrago, Esther del Olmo, Juan A Mico, Mario F Guerrero
• Journal: Life sciences (Life Sci) Vol. 86 Issue 21-22 Pg. 819-24 (May 22 2010) ISSN: 1879-0631 [Electronic] Netherlands
• PMID: 20394758 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 4-propyl-2H-benzo(h)chromen-2-one
• Antidepressive Agents
• Chromones
• Monoamine Oxidase Inhibitors

Topics

• Animals
• Antidepressive Agents (pharmacology)
• Behavior, Animal (drug effects)
• Central Nervous System (drug effects)
• Chromones (pharmacology)
• Dose-Response Relationship, Drug
• Male
• Mice
• Mice, Inbred ICR
• Monoamine Oxidase Inhibitors (pharmacology)
• Seizures (drug therapy)
• Sleep (drug effects)